Anti-LRRK2 antibody [MJFF5 (68-7)] (ab181386)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [MJFF5 (68-7)] to LRRK2
- Suitable for: WB
- Knockout validated
- Reacts with: Mouse, Human
Overview
-
Product name
Anti-LRRK2 antibody [MJFF5 (68-7)]
See all LRRK2 primary antibodies -
Description
Rabbit monoclonal [MJFF5 (68-7)] to LRRK2 -
Host species
Rabbit -
Tested Applications & Species
See all applications and species dataApplication Species WB Human -
Immunogen
This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- Human brain cortex and mouse brain cortex lysates.
-
General notes
Well-characterized antibodies to efficiently detect and purify LRRK2 protein are a critical need in the Parkinson's Disease (PD) research community. To help accelerate LRRK2 research, The Michael J. Fox Foundation (MJFF), working with Epitomics, Inc., has generated unique and high quality LRRK2 rabbit monoclonal antibodies to be widely available for PD research community.
LRRK2 (Leucine-rich repeat kinase 2, dardarin) is a protein kinase belonging to the ROCO family, which is defined by the presence of a ROC (Ras/GTPase of complex proteins) domain and COR (C-terminal of Roc) region. LRRK2 exhibits kinase activity whereby it can undergo autophosphorylation and can phosphorylate generic substrates. In addition, the GTPase domain of LRRK2 can mediate GDP (guanosine-5′-diphosphate)/GTP (guanosine-5′-triphosphate) binding as well as GTP hydrolysis.
LRRK2 is mutated in a significant number of Parkinson's disease (PD) patients. Mutations in this gene account for 4% of PD, and are observed in 1% of sporadic PD patients. Clinical symptoms of patients carrying PD-associated mutations of LRRK2 are indistinguishable from typical sporadic PD. The spectra of neuropathological features of PARK8 (type 8), the type corresponding to LRRK2, is broad and appears to encompass those associated with other familial PD cases such as PARK1 (alpha-synuclein) and PARK2 (Parkin). Patients with this gene mutation have typical relatively late onset Parkinsonism with features comparable with idiopathic PD; symptoms include asymmetric rest tremor, bradykinesia, rigidity, and a good response to 3,4-dihyroxy-l-phenylalanine (l-DOPA). The pathology of cases with LRRK2 mutations is pleomorphic.
This antibody clone (c68-7) has been re-introduced to the Epitomics catalog as characterization efforts have indicated that it performs very well at immunoprecipitating LRRK2 protein from cell lines and tissue lysate. This may facilitate investigators’ ability to more broadly examine alterations in LRRK2 protein levels and activity to interrogate changes in the biological samples.
For more characterization data and protocols using this LRRK2 Antibody, please refer to Davies, et al. 2013. Biochemical J 453(1):101-113 [PMID: 23560750]
Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituent: 99% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
MJFF5 (68-7) -
Isotype
IgG -
Research areas
Images
-
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: LRRK2 knockout HAP1 cell lysate (20 µg)
Lane 3: MEF cell lysate (20 µg)
Lane 4: LRRK2 knockout MEF cell lysate (20 µg)
Lane 5: A549 cell lysate (20ug)
Lane 6: LRRK2 knockout A549 cell lysate (20 µg)Lanes 1 - 6: Merged signal (red and green). Green - ab181386 observed at 238 kDa. Red - loading control, ab18058, observed at 124 kDa.
ab181386 was shown to specifically react with wildtype HAP1, MEF and A549 cell lysates with additional cross-reactive bands. No bands were observed when LRRK2 knockout samples were used. Wild-type and LRRK2 knockout samples were subjected to SDS-PAGE. Membranes were blocked in 3% milk for 1 hour at room temperature. ab181386 and ab130007 (loading control to Vinculin) were diluted at 2.5 ug/mL and 1/10000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.
Wild-type and LRRK2 knockout MEF and A549 cells were provide as a generous gift from Professor Dario Alessi, MRC Protein Phosphorylation and Ubiquitination Unit (University of Dundee).
-
All lanes : Anti-LRRK2 antibody [MJFF5 (68-7)] (ab181386) at 1 µg/ml
Lanes 1-2 : Human brain cortex lysate
Lane 3 : mouse brain cortex lysate
Lane 4 : LRRK2-knock-out mouse brain cortex lysate
Developed using the ECL technique.
Predicted band size: 286 kDa
-